PerkinElmer Gets ViaCord Stem Cell Preserver In $300 Mil. ViaCell Deal
This article was originally published in The Gray Sheet
Health sciences giant PerkinElmer will expand its neonatal offerings with its $300 million acquisition of ViaCell, announced Oct. 1
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.